Evidence map›Paper›PMID 26147064›Full record

ArticleBiotechnology progress

A purification process for heparin and precursor polysaccharides using the pH responsive behavior of chitosan.

Ujjwal Bhaskar, Anne M Hickey, Guoyun Li, Ruchir V Mundra, Fuming Zhang, Li Fu, Chao Cai, Zhimin Ou, Jonathan S Dordick, Robert J Linhardt

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biotechnology progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Bioengineered heparins and heparan sulfates.Advanced drug delivery reviews · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Ujjwal BhaskarDept. of Chemical and Biological Engineering, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY.
Anne M HickeyDept. of Chemical and Biological Engineering, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY.
Guoyun LiDept. of Chemical and Biological Engineering, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY.
Ruchir V MundraDept. of Chemical and Biological Engineering, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY.
Fuming ZhangDept. of Chemical and Biological Engineering, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY.
Li FuDept. of Chemistry and Chemical Biology, Rensselaer Polytechnic Institute, Troy, NY.
Chao CaiDept. of Chemistry and Chemical Biology, Rensselaer Polytechnic Institute, Troy, NY.
Zhimin OuDept. of Chemistry and Chemical Biology, Rensselaer Polytechnic Institute, Troy, NY.
Jonathan S DordickDept. of Chemical and Biological Engineering, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY.
Robert J LinhardtDept. of Chemical and Biological Engineering, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY.
Rensselaer Polytechnic Institute · US

Funding

In vitro synthesis of recombinant heparan sulfateR01HL094463 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LIU, JIAN, PAWLINSKI, RAFAL L · 2009 to 2021
$5.2M
Synthetic Heparan Sulfate: Probing Biosynthesis to Prepare Defined DrugsR01HL062244 · NHLBI · UNIVERSITY OF IOWA · PI DEANGELIS, PAUL L, LINHARDT, ROBERT J · 2001 to 2016
$4.1M
Development of a Bioengineered Heparin from a Non-Animal SourceR01HL096972 · NHLBI · RENSSELAER POLYTECHNIC INSTITUTE · PI DORDICK, JONATHAN S., LINHARDT, ROBERT J · 2009 to 2013
$3.9M
SEQUENCING THE POLYSACCHARIDE COMPONENT OF PROTEOGLYCANSR01GM038060 · NIGMS · UNIVERSITY OF IOWA · PI LINHARDT, ROBERT J · 1988 to 2012
$2.8M
NHLBI NIH HHS HL094463NHLBI NIH HHS HL096972NHLBI NIH HHS HL62244NHLBI NIH HHS R01 HL062244NHLBI NIH HHS R01 HL094463NHLBI NIH HHS R01 HL096972NIGMS NIH HHS GM38060NIGMS NIH HHS R01 GM038060
6 · The paper itself

Abstract

The contamination crisis of 2008 has brought to light several risks associated with use of animal tissue derived heparin. Because the total chemical synthesis of heparin is not feasible, a bioengineered approach has been proposed, relying on recombinant enzymes derived from the heparin/HS biosynthetic pathway and Escherichia coli K5 capsular polysaccharide. Intensive process engineering efforts are required to achieve a cost-competitive process for bioengineered heparin compared to commercially available porcine heparins. Towards this goal, we have used 96-well plate based screening for development of a chitosan-based purification process for heparin and precursor polysaccharides. The unique pH responsive behavior of chitosan enables simplified capture of target heparin or related polysaccharides, under low pH and complex solution conditions, followed by elution under mildly basic conditions. The use of mild, basic recovery conditions are compatible with the chemical N-deacetylation/N-sulfonation step used in the bioengineered heparin process. Selective precipitation of glycosaminoglycans (GAGs) leads to significant removal of process related impurities such as proteins, DNA and endotoxins. Use of highly sensitive liquid chromatography-mass spectrometry and nuclear magnetic resonance analytical techniques reveal a minimum impact of chitosan-based purification on heparin product composition.

Indexed as

Bacterial CapsulesBioengineeringChitosanChromatography, LiquidDisaccharidesEscherichia coliFermentationGlycosaminoglycansHeparinHydrogen-Ion ConcentrationMagnetic Resonance ImagingMass SpectrometryMolecular Weightcapsular polysaccharide K5ChitosanDisaccharidesGlycosaminoglycansHeparinheparosanbioengineered heparinliquid chromatography-mass spectrometry (LC-MS)nuclear magnetic resonance (NMR)polyelectrolyte based purificationUnited States Pharmacopeia (USP)

Identifiers

PMID26147064
PMCPMC4652654
OpenAlexW2131218644

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.